The ODYSSEY DM-DYSLIPIDEMIA trial: Confirming the benefits of alirocumab in diabetic mixed dyslipidemia

Paul Chan, Li Shao, Brian Tomlinson, Zhong Min Liu

Research output: Contribution to journalEditorial

Original languageEnglish
Article number477
JournalAnnals of Translational Medicine
Volume5
Issue number23
DOIs
Publication statusPublished - Dec 1 2017

Fingerprint

Dyslipidemias
alirocumab

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The ODYSSEY DM-DYSLIPIDEMIA trial : Confirming the benefits of alirocumab in diabetic mixed dyslipidemia. / Chan, Paul; Shao, Li; Tomlinson, Brian; Liu, Zhong Min.

In: Annals of Translational Medicine, Vol. 5, No. 23, 477, 01.12.2017.

Research output: Contribution to journalEditorial

@article{0572c1e58f524b338d5f7c0cd122b1d3,
title = "The ODYSSEY DM-DYSLIPIDEMIA trial: Confirming the benefits of alirocumab in diabetic mixed dyslipidemia",
author = "Paul Chan and Li Shao and Brian Tomlinson and Liu, {Zhong Min}",
year = "2017",
month = "12",
day = "1",
doi = "10.21037/atm.2017.10.26",
language = "English",
volume = "5",
journal = "Annals of Translational Medicine",
issn = "2305-5839",
publisher = "AME Publishing Company",
number = "23",

}

TY - JOUR

T1 - The ODYSSEY DM-DYSLIPIDEMIA trial

T2 - Confirming the benefits of alirocumab in diabetic mixed dyslipidemia

AU - Chan, Paul

AU - Shao, Li

AU - Tomlinson, Brian

AU - Liu, Zhong Min

PY - 2017/12/1

Y1 - 2017/12/1

UR - http://www.scopus.com/inward/record.url?scp=85037134727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037134727&partnerID=8YFLogxK

U2 - 10.21037/atm.2017.10.26

DO - 10.21037/atm.2017.10.26

M3 - Editorial

AN - SCOPUS:85037134727

VL - 5

JO - Annals of Translational Medicine

JF - Annals of Translational Medicine

SN - 2305-5839

IS - 23

M1 - 477

ER -